Value of Platelet-Rich Plasma in Post Severe Acute Respiratory Syndrome Coronavirus 2
1 other identifier
interventional
88
0 countries
N/A
Brief Summary
The study will be conducted to evaluate : The efficacy of Platelet Rich plasma in treatment of smell disorders post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the growth factors involved in accelerating and enhancing healing.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started Jun 2022
Shorter than P25 for early_phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 6, 2022
CompletedFirst Posted
Study publicly available on registry
May 27, 2022
CompletedStudy Start
First participant enrolled
June 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2023
CompletedMay 27, 2022
May 1, 2022
6 months
March 6, 2022
May 25, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Change From Baseline in Loss of Smell on the Olfactory Determination etermination Rating scale for COVID-19 (ODoR-19) at 6 Weeks
40 of Participants With Treatment will be improved
baseline
Study Arms (1)
value of platlet rich plasma
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- patient age above 18 who suffer from anosmia post severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 more than two weeks
- Normal airway passage
- CT Nose and Para nasal sinuses does not show any nasal lesion
You may not qualify if:
- Lesions obstruct airway as nasal polyps, tumors, chronic sinusitis and severe nasal septum deviation
- Previous Sino nasal surgery
- Atrophic rhinitis
- Diabetic patients and those with medical history of bleeding disorders
- Recieving any medication affect platelets or bone marrow function for 2 weeks prior to testing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.
PMID: 32167747BACKGROUNDChen X, Fang H, Schwob JE. Multipotency of purified, transplanted globose basal cells in olfactory epithelium. J Comp Neurol. 2004 Feb 16;469(4):457-74. doi: 10.1002/cne.11031.
PMID: 14755529BACKGROUNDWoo SH, Jeong HS, Kim JP, Koh EH, Lee SU, Jin SM, Kim DH, Sohn JH, Lee SH. Favorable vocal fold wound healing induced by platelet-rich plasma injection. Clin Exp Otorhinolaryngol. 2014 Mar;7(1):47-52. doi: 10.3342/ceo.2014.7.1.47. Epub 2014 Feb 5.
PMID: 24587881BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 6, 2022
First Posted
May 27, 2022
Study Start
June 1, 2022
Primary Completion
December 1, 2022
Study Completion
January 1, 2023
Last Updated
May 27, 2022
Record last verified: 2022-05